Clinical Trials Logo

Allosensitization clinical trials

View clinical trials related to Allosensitization.

Filter by:
  • None
  • Page 1

NCT ID: NCT05862766 Not yet recruiting - Clinical trials for Antibody-mediated Rejection

Isatuximab in Lung Transplant Recipients

Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and feasibility of adding isatuximab to standard of care therapies in patients who will receive a lung transplant, but have significant antibodies against the donor (desensitization), or patients who have previously received a lung transplant and develop antibodies against the donor (antibody-mediated rejection, AMR). The study will compare the impact of isatuximab on the recurrence of antibodies after they have been removed from the blood by a process known as plasmapheresis that is standard of care for this condition. The use of isatuximab in lung transplant recipients is investigational, meaning it is not Food and Drug Administration (FDA) approved for use in lung transplant recipients. This study is a pilot study investigating the feasibility and safety of isatuximab in lung transplant patients. Isatuximab is an FDA approved drug indicated for the treatment of multiple myeloma. It may also be useful for transplant recipients with antibodies against the donor because it eliminates the cells that make antibodies.

NCT ID: NCT04610320 Completed - Clinical trials for Heart Transplant Failure and Rejection

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation. These preformed antibodies limit the number of donor hearts that are compatible for the patients. If Daratumumab-SC can effectively remove preformed, donor-specific antibodies, then highly allosensitized patients will have more compatible hearts available to them, potentially decreasing transplant waitlist time and reducing mortality.

NCT ID: NCT04204980 Completed - Clinical trials for Kidney Transplant Rejection

Desensitization in Kidney Allograft Using Daratumumab

DARDAR
Start date: February 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Patients highly allosensitized against HLA antigen awaiting for a kidney transplant have less compatible transplants to them, increasing their waitlist time and mortality. Current desensitization strategies need to be improved with a high remaining acute rejection rate in this population and a substantial survival benefit which is not uniformly reported in the literature. The investigators propose to use daratumumab, a human IgG1 (Immunoglobulin Gamma-1) monoclonal antibody directed against the CD38 molecule (cluster of differentiation 38) witch induce response in refractory multiple myeloma by depleting plasma cells, as a new agent of desensitization. The study will address the hypothesis that daratumumab can lead to a significant decrease in calculated panel reactive antibodies by elimination of anti-HLA antibodies-producing plasma cells and facilitate the access to transplantation with a safety profile in highly sensitized patients registered in our kidney transplantation center.

NCT ID: NCT04088903 Withdrawn - Clinical trials for Heart Transplant Failure and Rejection

Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test whether daratumumab, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation. These preformed antibodies limit the number of donor hearts that are compatible for the patients. If daratumumab can effectively remove preformed, donor-specific antibodies, then highly allosensitized patients will have more compatible hearts available to them, potentially decreasing transplant waitlist time and reducing mortality.

NCT ID: NCT03689075 Recruiting - Immunosuppression Clinical Trials

Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation

EVITRA
Start date: November 1, 2018
Phase: Phase 4
Study type: Interventional

Study to compare once-daily extended release tacrolimus versus twice-daily immediate release tacrolimus following renal allograft failure to reduce the risk of allosensitisation